Last updated: June 23, 2026

Piperacillin sodium plus tazobactam sodium is a mature, off-patent, broad-spectrum hospital antibiotic with a procurement-driven market. Price compression and stable-to-slow unit growth define the financial trajectory, with gross margin largely determined by contracting, tender wins, and supply execution. Competitive pressure is high because the core product is widely available in multiple authorized generics and contracted sources, making brand economics dependent on remaining exclusivity for specific presentations and on payer and provider formulary position rather than on fundamental demand growth.

What drives market dynamics for piperacillin sodium/tazobactam in hospitals?

Short answer: Demand is tied to inpatient sepsis, intra-abdominal infection, pneumonia, and complicated skin/soft tissue infection pathways. Competitive dynamics are dominated by group purchasing organization (GPO) contracting, national and regional tender processes, and supply reliability rather than new clinical differentiation.

Where is utilization concentrated by indication and care setting?

Inpatient acute care: Emergency department to inpatient transitions, ICU sepsis pathways, and surgical service infection bundles.
ICU use: Empiric broad-spectrum antibiotic selections that require coverage of gram-negative organisms and anaerobes.
Surgical and GI services: Complicated intra-abdominal infections and post-operative infections.
Hospital formularies: Often managed via antimicrobial stewardship with required approvals, preauthorization, or automatic substitution rules.

What procurement levers move unit volume and revenue?

Tender cycles (quarterly to annual) that lock pricing for a defined hospital network.
Contracted unit pricing that can move the blended price faster than list price changes.
Substitution behavior: Hospitals typically treat interchangeable versions as equivalents at the point of purchase, prioritizing acquisition cost and availability.

How do shortages and supply constraints impact price and earnings?

Supply disruptions in sterile injectables can temporarily widen pricing spreads.
Even for mature products, allocation events can raise near-term revenue and margins for the constrained supplier, but this tends to normalize once capacity returns.

When does piperacillin sodium/tazobactam lose exclusivity, and what does that mean for pricing?

Short answer: The drug combination is widely off patent as a therapy class, so practical “exclusivity” is presentation- and manufacturer-specific, including possible residual exclusivity for certain strengths, container systems, kits, or labeling-related exclusivities. The core market behavior follows generic penetration, not patent sunset timing.

What exclusivity typically exists for mature antibiotic combination products?

For older injectables, exclusivity may come from:

Orange Book-listed patents tied to specific formulations or manufacturing methods (when present).
NDA or ANDA-specific exclusivities for particular product configurations (strength, container/packaging, reconstitution system).
Brand-specific REMS or labeling mechanisms is less common for this class because antibiotics rarely carry REMS in the US.

How does generic entry affect blended market revenue?

Price compression typically follows:
1. First generic launch, then
2. Competition among multiple authorized generics and ANDA filers, and then
3. Contracting that drives net prices toward the low end of the competitive set.
Net revenue growth, when it occurs, usually comes from volume offsets like higher admissions or more ICU throughput, not from price.

What patents protect piperacillin sodium/tazobactam, and how strong is the remaining estate?

Short answer: For this drug combination, the legal landscape is generally characterized by an off-patent active ingredient profile with residual protection (if any) limited to specific Orange Book-listed patents on product-specific aspects. The residual estate typically affects only certain SKUs or manufacturing variants, not the entire combination therapy.

How to interpret patent estate strength in mature antibiotic markets

Even if a patent remains listed for certain presentations, hospital purchasing commonly sources equivalent products from multiple suppliers.
Enforcement risk is usually concentrated in the subset of manufacturers that make the protected variant rather than the whole molecule.

How many patents cover piperacillin/tazobactam, and where do they tend to sit?

In mature injectables, patent lists often cluster around:
- Formulation and composition,
- Manufacturing process steps,
- Container closure systems and stability,
- Method-of-use claims (less common for broadly indicated antibiotics after many years).

No patent numbers or Orange Book listings were provided in the prompt; without those, a complete patent-by-patent estate map cannot be produced.

What generic entry risks exist for piperacillin sodium/tazobactam?

Short answer: Generic entry risk is structurally high but commercially normalized because multiple competing sources already exist. The risk that matters is less “whether generics will enter” and more “whether a particular manufacturer’s product is blocked by formulation-specific patents or litigation.”

What filings matter in this category?

Paragraph IV challenges generally become relevant if Orange Book-listed patents remain active for a specific product configuration.
For widely available combinations, Paragraph IV waves often occur earlier in lifecycle; later rounds typically target leftover, presentation-specific protections.

What drives time-to-market outcomes for new ANDAs here?

Sterile manufacturing capacity
Stability data for the specific packaging configuration
Bioequivalence demonstrations for dosage forms
Regulatory readiness for lot release timelines

What is the Orange Book status of piperacillin sodium/tazobactam?

Short answer: The combination is generally treated as off-patent at the active ingredient level, with any remaining Orange Book impact tied to specific NDA/ANDA product listings and specific patent expiration dates. A precise Orange Book status table cannot be generated without the exact listed NDA and the associated patent list.

How does piperacillin sodium/tazobactam compare with other IV beta-lactam/beta-lactamase inhibitor antibiotics on market dynamics?

Short answer: Competition is strongest against:

Other penicillin/beta-lactamase inhibitor combinations,
Carbapenems (for severe infections),
Cephalosporin/beta-lactamase inhibitor regimens,
Antipseudomonal cephalosporins depending on antibiogram.

Key competitive dimensions

Spectrum fit to antibiogram and stewardship policies
Cost per day under contracting
Formulary placement linked to infection pathways
Admin convenience (dose stability, reconstitution workflow, packaging)
Availability and reliability under seasonal or capacity constraints

What FDA regulatory factors affect sales and manufacturing continuity?

Short answer: For mature injectable antibiotics, the primary regulatory factors are manufacturing site performance, sterile product quality systems, and post-approval variation management that preserve continuous supply.

Common operational regulatory constraints in sterile injectables

Process validation and ongoing PPQ verification
Sterility assurance controls
Stability under container closure configurations
Variations for scale-up or equipment changes

What financial trajectory does piperacillin sodium/tazobactam follow as a mature hospital antibiotic?

Short answer: Revenue growth is usually modest and tied to hospital volume and mix, while price is largely contract-driven and tends to decline or remain flat in net terms after generic penetration. Profitability depends on how well manufacturers capture contracted volume and avoid quality-related disruptions.

Typical lifecycle pattern for this class

Early years: brand or limited generic competition supports higher net prices.
Midlife: authorized generics increase share and push blended price down.
Later: price becomes anchored by tender bids, and financial upside comes from supply reliability and cost-down manufacturing.

What metrics are most predictive

Contracted net price per vials/grams by region or network
Volume units shipped under major GPOs
Manufacturing yield and lot release performance
Gross margin after rebates/chargebacks and freight
Inventory turns and working capital efficiency

No company-specific financials were provided, so a quantified revenue and margin trajectory cannot be constructed.

What settlement and litigation dynamics matter for this drug?

Short answer: Settlement matters when it changes who supplies the protected SKU or when it delays generic launch. For mature antibiotics, litigation can still move the competitive set, but it generally affects a narrower set of product configurations rather than the entire market.

How litigation usually shows up commercially

A particular ANDA may be delayed for a protected strength or packaging.
Settlement can lead to:
- Authorized generic launch at a later date,
- Exclusivity carve-outs by market segment,
- Consent decrees on manufacturing design.

No litigation docket details were provided in the prompt; a litigation impact table cannot be produced.

How do procurement and reimbursement economics shape total market revenue?

Short answer: Inpatient purchasing is dominated by hospital pharmacy procurement economics with reimbursement only indirectly affecting volume via admission rates and case mix. Net revenue depends on contracted purchase prices rather than acquisition cost at wholesale.

What bargaining dynamics exist

GPO-negotiated price bands
Multi-supplier panels where hospitals retain multiple bids
Stewardship-driven formulary preferences

What causes revenue swings

Supply shortages or manufacturing interruptions
Changes in hospital antimicrobial guidelines
Seasonal shifts in infection incidence
Payer and hospital budgeting that changes formulary position

Key commercial outlook for piperacillin/tazobactam through the next contract cycles

Short answer: The base case is stable volume with continued price pressure. The biggest upside is not clinical innovation but share capture, efficient sterile manufacturing, and avoidance of supply interruptions. The biggest downside is margin compression from intensified tender competition or quality/supply setbacks.

Business scenarios

Best case: Contract wins in high-volume networks combined with stable supply and cost-down manufacturing.
Base case: Stable contracted pricing with incremental share shifts and normal seasonal demand variation.
Downside: Margin compression if price bids converge downward, or if a key supplier faces manufacturing disruption that does not translate into sustained higher pricing because competing suppliers cover demand.

Key Takeaways

Piperacillin sodium/tazobactam is a mature hospital antibiotic with demand anchored in inpatient infection care pathways and procurement-driven pricing.
The financial trajectory is characterized by generic penetration, contract-based net pricing, and margin sensitivity to manufacturing reliability and tender wins.
Residual patent and exclusivity effects, where they exist, are typically tied to specific product presentations rather than the entire combination therapy.
For forward-looking planning, the most actionable levers are supply readiness, cost positioning, and contract strategy, not molecule-level innovation.

FAQs

How do hospital tender cycles impact net revenue for piperacillin sodium/tazobactam?
Net revenue is set primarily by contracted bid prices and GPO terms, so quarterly to annual tender resets can move blended pricing faster than list price changes.
Does switching to alternative beta-lactam/beta-lactamase inhibitors materially reduce piperacillin/tazobactam demand?
Demand shifts occur through formulary and stewardship decisions, but volume typically reallocates across the class rather than collapsing because infection pathways still require broad empiric coverage.
What is the biggest risk to margins for mature IV antibiotics like piperacillin/tazobactam?
Margin is most sensitive to price compression from competitive contracting and to cost increases from sterile manufacturing disruptions or lower yields.
Can a single protected SKU meaningfully change competition in the overall market?
Yes, for specific strengths or packaging configurations, but hospital purchasing often sources equivalents, limiting broad market impact.
Do supply shortages create sustained financial upside for this drug class?
Usually not. They can lift near-term revenue and margins, but sustained pricing power is limited once competing suppliers expand shipments and contracts reprice.

References

(No sources were provided or can be cited from the prompt; therefore, no references are listed.)

US Patents:	0
Tradenames:	4
Applicants:	16
NDAs:	25
Finished Product Suppliers / Packagers:	17
Clinical Trials:	5
DailyMed Link:	piperacillin sodium; tazobactam sodium at DailyMed

Sponsor	Phase
M.D. Anderson Cancer Center	Phase 2
St. Justine's Hospital	Phase 1
Phillip Brian Smith	Phase 1

Drug Class	Penicillin-class Antibacterial beta Lactamase Inhibitor
Mechanism of Action	beta Lactamase Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shandong	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	204959-002	Aug 10, 2018	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Fresenius Kabi	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	203720-001	May 11, 2018	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sandoz	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	065362-002	Oct 21, 2010	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hospira Inc	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	065386-001	Sep 15, 2009		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Istituto Bio Ita Spa	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	065523-002	May 31, 2011	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
B Braun Medical	PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER	piperacillin sodium; tazobactam sodium	POWDER;INTRAVENOUS	206056-002	Apr 3, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sagent Pharms Inc	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	208675-001	Feb 16, 2021	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-003	Feb 24, 1998	6,900,184	⤷ Start Trial
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-003	Feb 24, 1998	7,915,229	⤷ Start Trial
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-002	Feb 24, 1998	8,133,883	⤷ Start Trial
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-002	Oct 22, 1993	6,900,184	⤷ Start Trial
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-004	Oct 22, 1993	7,915,229	⤷ Start Trial
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-002	Oct 22, 1993	8,133,883	⤷ Start Trial
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-001	Feb 24, 1998	8,133,883	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Summary for piperacillin sodium; tazobactam sodium

Recent Clinical Trials for piperacillin sodium; tazobactam sodium

Pharmacology for piperacillin sodium; tazobactam sodium

Anatomical Therapeutic Chemical (ATC) Classes for piperacillin sodium; tazobactam sodium

Paragraph IV (Patent) Challenges for PIPERACILLIN SODIUM; TAZOBACTAM SODIUM